On the other hand, OTUD7B upregulation more significantly (p < 0.05) predicted a poor RFS probability in patients receiving post-operative paclitaxel chemotherapy with unclassified (Figure 6C) and basal-like (Figure 6D) breast cancer. Here, OTUD7B is linked to breast carcinoma.